Overview
CAR-T cell therapy has transformed the treatment of relapsed and refractory blood cancers — offering hope to patients who have exhausted conventional treatment options. China is now at the forefront of CAR-T innovation, with Shanghai's leading hematology centers pioneering the development and clinical application of domestically produced CAR-T products. At the center of this revolution is a Shanghai hematologist whose department has been ranked number one among Shanghai municipal hospital hematology departments in clinical service capability — and who played a pivotal role in bringing China's first domestically approved lymphoma CAR-T product to market.
China Medical Concierge Shanghai (CMCS) connects international patients with Shanghai's top hematology specialists, providing end-to-end support from remote consultation through to post-treatment follow-up.
Understanding Lymphoma & Multiple Myeloma
Lymphoma
Lymphoma is a cancer of the lymphatic system arising from lymphocytes. Non-Hodgkin lymphoma (NHL) encompasses over 60 subtypes, ranging from indolent to highly aggressive. The most common aggressive subtype is diffuse large B-cell lymphoma (DLBCL), which accounts for approximately 30–35% of all NHL cases. Despite high initial response rates to first-line chemoimmunotherapy (R-CHOP), approximately 30–40% of patients relapse or have refractory disease — and it is in this setting that CAR-T therapy has had its most dramatic impact.
Multiple Myeloma
Multiple myeloma is a cancer of plasma cells — antibody-producing cells in the bone marrow. It is the second most common blood cancer and remains incurable with standard therapy, though outcomes have improved dramatically with the introduction of novel agents (proteasome inhibitors, immunomodulatory drugs, anti-CD38 monoclonal antibodies, and CAR-T therapy). Key features include:
- Bone pain and pathological fractures
- Anaemia and fatigue
- Renal impairment
- Hypercalcaemia
- Recurrent infections
- Elevated serum protein (M-protein) on electrophoresis
Common Symptoms of Lymphoma
- Painless lymph node swelling (neck, armpits, groin)
- Fever, night sweats, unexplained weight loss ("B symptoms")
- Fatigue and itching
- Shortness of breath (mediastinal involvement)
Treatment: CAR-T, Targeted Therapy & Comprehensive Care
CAR-T Cell Therapy for Lymphoma
CAR-T (chimeric antigen receptor T-cell) therapy is a form of personalized immunotherapy in which a patient's own T-cells are collected, genetically engineered to express a receptor targeting a cancer-specific antigen (typically CD19 for B-cell lymphoma), expanded in the laboratory, and infused back into the patient. In relapsed/refractory large B-cell lymphoma, CAR-T therapy achieves complete response rates of 40–54% — with durable long-term remissions in a significant proportion of patients.
China's first domestically produced lymphoma CAR-T product — developed and approved through a process in which Prof. Liu Peng's team played a central role — has made this transformative therapy more accessible to Chinese patients and represents a landmark achievement in China's biopharmaceutical innovation.
CAR-T Cell Therapy for Multiple Myeloma
For relapsed/refractory multiple myeloma, BCMA-targeted CAR-T therapy (ciltacabtagene autoleucel, idecabtagene vicleucel) has achieved remarkable response rates of 70–98% in heavily pre-treated patients — including those who have failed proteasome inhibitors, immunomodulatory drugs, and anti-CD38 antibodies. Shanghai is one of China's leading centers for myeloma CAR-T therapy.
Comprehensive Lymphoma Treatment
- First-line chemoimmunotherapy — R-CHOP and variants for DLBCL and follicular lymphoma
- Targeted therapy — BTK inhibitors (zanubrutinib, ibrutinib) for mantle cell lymphoma and CLL; BCL2 inhibitors (venetoclax); lenalidomide
- Bispecific antibodies — mosunetuzumab, glofitamab for relapsed/refractory B-cell lymphoma
- Autologous stem cell transplantation (ASCT) — for eligible relapsed/refractory patients achieving salvage response
- CAR-T therapy — for relapsed/refractory large B-cell lymphoma after two or more prior lines
Comprehensive Myeloma Treatment
- Induction therapy — VRd (bortezomib, lenalidomide, dexamethasone) or DRd (daratumumab, lenalidomide, dexamethasone)
- Autologous stem cell transplantation — for eligible newly diagnosed patients
- Maintenance therapy — lenalidomide-based maintenance after transplant
- Relapsed/refractory myeloma — anti-CD38 antibodies (daratumumab, isatuximab), carfilzomib, pomalidomide, selinexor, belantamab mafodotin
- BCMA-targeted CAR-T therapy — for heavily pre-treated relapsed/refractory myeloma
Why Choose Zhongshan Hospital for Lymphoma & Myeloma?
- Ranked #1 among Shanghai municipal hospital hematology departments in clinical service capability
- CAR-T therapy pioneer — Prof. Liu's team played a central role in bringing China's first domestically approved lymphoma CAR-T product to market
- Comprehensive treatment across all blood cancer subtypes — lymphoma, myeloma, leukemia, and related conditions
- Fudan University academic medical center — access to clinical research and novel treatment approaches
- Cost-effective world-class care — significantly lower cost than equivalent treatment in the US, UK, or Singapore
Featured Specialist: Prof. Liu Peng — Zhongshan Hospital, Fudan University
Prof. Liu Peng (刘澛) is a Professor of Hematology and Director of the Department of Hematology at Zhongshan Hospital, Fudan University — one of China's most prestigious academic medical centers. He serves as a Standing Committee Member of the Hematology Branch of the Chinese Medical Association — one of the most senior positions in Chinese hematology.
Ranked #1 Hematology Department in Shanghai
Under Prof. Liu's leadership, the Zhongshan Hospital Department of Hematology has been ranked first among Shanghai municipal hospital hematology departments in clinical service capability — a recognition that reflects the department's breadth of expertise, volume of complex cases, and quality of patient outcomes across all blood cancer subtypes.
CAR-T Pioneer: China's First Domestically Approved Lymphoma CAR-T
Prof. Liu played a pivotal role in the development and regulatory approval of China's first domestically produced lymphoma CAR-T cell product — a landmark achievement that has made this transformative therapy more accessible to Chinese patients and established Shanghai as a global center of CAR-T innovation. His leadership in this process reflects both his clinical expertise in CAR-T therapy and his commitment to advancing the field of blood cancer treatment in China.
Clinical Expertise
- Lymphoma — DLBCL, follicular lymphoma, mantle cell lymphoma, T-cell lymphomas, and relapsed/refractory disease
- Multiple myeloma — comprehensive treatment including novel agents, ASCT, and CAR-T therapy
- CAR-T cell therapy — CD19-targeted CAR-T for B-cell lymphoma; BCMA-targeted CAR-T for myeloma
- Autologous stem cell transplantation — for eligible lymphoma and myeloma patients
- Clinical trial access — novel agents and CAR-T constructs in development
For international patients, Prof. Liu's team offers remote pre-consultation review of biopsy pathology, molecular profiling, and prior treatment records, enabling a precise treatment recommendation to be developed before arrival in Shanghai.
How CMCS Supports Your Journey
CMCS is not a hospital — we are your dedicated medical concierge, providing a trusted bridge between international patients and Shanghai's finest cancer specialists.
Our services include:
- ✅ Direct appointment coordination with Prof. Liu Peng and the Zhongshan Hospital hematology team
- ✅ Pathology, molecular profiling, and prior treatment record translation and pre-consultation review
- ✅ CAR-T therapy eligibility assessment and coordination
- ✅ Second opinion facilitation
- ✅ Hospital admission and treatment scheduling support
- ✅ Accommodation and logistics coordination in Shanghai
- ✅ Post-treatment follow-up and remote check-in support
Contact CMCS
If you or a loved one has been diagnosed with lymphoma or multiple myeloma and would like to explore treatment options in Shanghai, our team is ready to help.
📧 Email: contract@medicalsh.com
💬 WhatsApp: https://wa.me/message/3AM6KAGCW2BAD1
🌐 Website: www.medicalsh.com
CMCS — China Medical Concierge Shanghai. Connecting international patients with Shanghai's finest specialists.
0 Kommentare